MedTrace Logo

Validation of a Molecular Prognostic Test for Eye Melanoma

NCT00406120 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2018-06-26

No results posted yet for this study

Summary

Up to half of patients with ocular melanoma (also called iris, choroidal or uveal melanoma) develop metastasis. We have found that certain molecular features of the eye tumor can be detected by gene expression profiling and accurately predict which patients will develop metastasis. This molecular test could eventually allow high risk patients to receive preventative therapy to delay or prevent the development of metastasis. The goal of this study is to prospectively validate the predictive accuracy of the gene expression-based molecular test and compare it to monosomy 3, the most common but potentially less accurate molecular marker for metastasis in ocular melanoma.

Conditions

  • Uveal Neoplasms
  • Choroid Neoplasms
  • Iris Neoplasms

Interventions

PROCEDURE

Fine needle aspiration biopsy

Sponsors & Collaborators

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • J. William Harbour, MD · Washington University School of Medicine

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00406120 on ClinicalTrials.gov